Scarica l'app Stockscreener
0.92
1.88%
0.017
Precedente Chiudi:
$0.903
Aprire:
$0.93
Volume 24 ore:
45,636
Relative Volume:
0.60
Capitalizzazione di mercato:
$30.07M
Reddito:
-
Utile/perdita netta:
$-563.30K
Rapporto P/E:
-0.3538
EPS:
-2.6
Flusso di cassa netto:
$-22.23M
1 W Prestazione:
-1.08%
1M Prestazione:
-7.74%
6M Prestazione:
-40.65%
1 anno Prestazione:
-20.17%
Intervallo 1D:
$0.9003
$0.95
Intervallo di 1 settimana:
$0.87
$0.955
Portata 52W:
$0.87
$3.10
Promis Neurosciences Inc Stock (PMN) Company Profile
Nome
Promis Neurosciences Inc
Settore
Industria
Telefono
416-847-6898
Indirizzo
SUITE 200, 1920 YONGE STREET, TORONTO
Confronta PMN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
0.92 | 30.07M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Promis Neurosciences Inc Borsa (PMN) Ultime notizie
ProMIS Neurosciences stock hits 52-week low at $0.88 - Investing.com
ProMIS Neurosciences, Inc. (NASDAQ:PMN) Short Interest Down 16.6% in November - Defense World
ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference - GlobeNewswire
ProMIS Neurosciences stock hits 52-week low at $0.91 - Investing.com
ProMIS Neurosciences stock hits 52-week low at $0.91 By Investing.com - Investing.com Australia
ProMIS Neurosciences Announces Third Quarter Financial Results and Recent HighlightsOn November 14, 2024, ProMIS Neurosciences Inc. (Nasdaq: PMN) shared its financial outcomes for the third quarter ended September 30, 2024. The company provide - Defense World
ProMIS Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
GREAT POINT PARTNERS LLC Acquires Shares in ProMIS Neurosciences Inc - GuruFocus.com
ProMIS Neurosciences Inc (PMN) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in ProMIS Neurosciences Inc - GuruFocus.com
ProMIS Neurosciences Inc Reports Q3 2024 GAAP EPS of $0.31, Surp - GuruFocus.com
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights - GlobeNewswire
ProMIS Reports Positive Phase 1a Results for Alzheimer's Drug, Secures $30.3M Financing | PMN Stock News - StockTitan
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference - GlobeNewswire
ProMIS Neurosciences to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - The Manila Times
ProMIS Neurosciences (STU:23J0) PensionAndRetirementBenefit : €0.43 Mil (As of Jun. 2024) - GuruFocus.com
Biotech Shares Positive Phase I Data for Alzheimer's Treatment - Streetwise Reports
Capricor Therapeutics (CAPR) Faces 5% Drop Amid Industry Slump - GuruFocus.com
ProMIS Neurosciences Presents Positive Data from PMN310 - GlobeNewswire
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference - StockTitan
ProMIS Neurosciences, Inc. (NASDAQ:PMN): Among The 10 Oversold Canadian Stocks to Buy Right Now - Insider Monkey
ProMIS Neurosciences stock hits 52-week low at $0.92 - Investing.com India
ProMIS Neurosciences stock hits 52-week low at $0.92 By Investing.com - Investing.com South Africa
ProMIS Neurosciences, Inc. (PMN): Analysts Are Bullish On This Undervalued Canadian Stock Now - Insider Monkey
ProMIS Neurosciences appoints new CEO Neil Warma By Investing.com - Investing.com Australia
ProMIS Neurosciences appoints new CEO Neil Warma - Investing.com
ProMIS Neurosciences Names Neil Warma Permanent CEO - TipRanks
ProMIS Neurosciences (NASDAQ:PMN) versus Rigel Pharmaceuticals (NASDAQ:RIGL) Head-To-Head Analysis - Defense World
ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying - MSN
Director Madge Shafmaster Acquires 200,000 Shares of ProMIS Neur - GuruFocus.com
ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Madge K. Shafmaster Acquires 60,000 Shares - Defense World
ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Buys $89,600.00 in Stock - Defense World
ProMIS Neurosciences director Shafmaster purchases $255,750 in stock By Investing.com - Investing.com South Africa
ProMIS Neurosciences director Shafmaster purchases $255,750 in stock - Investing.com India
ProMIS Neurosciences (NASDAQ:PMN) versus Regulus Therapeutics (NASDAQ:RGLS) Critical Contrast - Defense World
BSE SME Popular Foundation slips on debut - Business Standard
Popular Foundations shares list at IPO price on BSE SME platform - The Economic Times
Popular Foundations makes tepid debut, shares list flat at ₹37 apiece on BSE SME platform - Upstox
How To Check Popular Foundations IPO Allotment Status - NDTV Profit
Taking a look at what insiders are doing to gauge the PureCycle Technologies Inc (PCT)’s direction - Knox Daily
Popular Foundations IPO allotment to be finalized today - IPO Watch
Promis Neurosciences Inc Azioni (PMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Promis Neurosciences Inc Azioni (PMN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shafmaster Madge K. | Director |
Sep 23 '24 |
Buy |
1.28 |
70,000 |
89,656 |
138,333 |
| Shafmaster Madge K. | Director |
Sep 20 '24 |
Buy |
1.25 |
60,000 |
75,066 |
68,333 |
| GORDON MICHAEL S | 10% Owner |
Sep 16 '24 |
Buy |
1.22 |
76,931 |
94,071 |
76,931 |
| GORDON MICHAEL S | 10% Owner |
Sep 17 '24 |
Buy |
1.40 |
16,292 |
22,809 |
93,223 |
| Kirwin Patrick D. | Director |
Aug 14 '24 |
Buy |
1.25 |
10,000 |
12,492 |
62,983 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):